Search by Drug Name or NDC
NDC 50474-0700-61 Cimzia Details
Cimzia
Cimzia is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by UCB, Inc.. The primary component is .
MedlinePlus Drug Summary
Certolizumab injection is used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) that has not improved when treated with other medications, rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function), psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin), active ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain, swelling, and joint damage) with changes seen on X-ray, active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas causing pain and signs of swelling), but without changes seen on X-ray, plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people who may benefit from medications or phototherapy (a treatment that involves exposing the skin to ultraviolet light). Certolizumab injection is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the activity of TNF, a substance in the body that causes inflammation.
Related Packages: 50474-0700-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Certolizumab Injection
Product Information
NDC | 50474-0700 |
---|---|
Product ID | 50474-700_f161a8e2-b6e2-27d7-e053-2995a90aa01c |
Associated GPIs | 52505020106420 |
GCN Sequence Number | 063903 |
GCN Sequence Number Description | certolizumab pegol KIT 400 MG SUBCUT |
HIC3 | S2J |
HIC3 Description | ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR |
GCN | 99615 |
HICL Sequence Number | 035554 |
HICL Sequence Number Description | CERTOLIZUMAB PEGOL |
Brand/Generic | Brand |
Proprietary Name | Cimzia |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | certolizumab pegol |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | KIT |
Route | n/a |
Active Ingredient Strength | n/a |
Active Ingredient Units | n/a |
Substance Name | n/a |
Labeler Name | UCB, Inc. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125160 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50474-0700-61 (50474070061)
NDC Package Code | 50474-700-61 |
---|---|
Billing NDC | 50474070061 |
Package | 2 KIT in 1 CARTON (50474-700-61) / 1 KIT in 1 KIT * 1 mL in 1 VIAL, GLASS * 1 mL in 1 VIAL, GLASS |
Marketing Start Date | 2008-04-20 |
NDC Exclude Flag | N |
Pricing Information | N/A |